Generic and Biosimilar Cancer Medicines
Estimated value
—
Awarded value
—
Suppliers
67
Lots
33
Published
21 Apr 2023
Description
This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland. The Goods were separated into forty-one (41) categories, each of which is identified as a “Lot”. Full details of each awarded Lot is contained in section II.2 of this Notice.
Scope
- Reference
- NP39722
- Commercial tool
- Standalone contract
- Contract dates
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Logistics | 5 | quality | — |
| — | 95 | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 33 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 33 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 Bendamustine Powder For Solution For Infusion | £95k | cancelled |
| 2 | Lot 2 Capecitabine Tablets | £911k | cancelled |
| 3 | Lot 3 Carboplatin Injection | £597k | cancelled |
| 4 | Lot 4 Cisplatin Injection | £186k | cancelled |
| 5 | Lot 5 Cyclophosphamide Injection, Powder For Reconstitution | £267k | cancelled |
Award 1· 1 supplier
Awarded —
Award 2· 1 supplier
Awarded —
Award 3· 1 supplier
Awarded —
Award 4· 1 supplier
Awarded —
Award 5· 1 supplier
Awarded —
Award 6· 1 supplier
Awarded —
Award 7· 1 supplier
Awarded —
Award 8· 1 supplier
Awarded —
Award 9· 1 supplier
Awarded —
Award 10· 1 supplier
Awarded —
Award 11· 1 supplier
Awarded —
Award 12· 1 supplier
Awarded —
Award 13· 1 supplier
Awarded —
Award 14· 1 supplier
Awarded —
Award 15· 1 supplier
Awarded —
Award 16· 1 supplier
Awarded —
Award 17· 1 supplier
Awarded —
Award 18· 1 supplier
Awarded —
Award 19· 1 supplier
Awarded —
Award 20· 1 supplier
Awarded —
Award 21· 1 supplier
Awarded —
Award 22· 1 supplier
Awarded —
Award 23· 1 supplier
Awarded —
Award 24· 1 supplier
Awarded —
Award 25· 1 supplier
Awarded —
Award 26· 1 supplier
Awarded —
Award 27· 1 supplier
Awarded —
Award 28· 2 suppliers
Awarded —
Award 29· 10 suppliers
Awarded —
Award 30· 1 supplier
Awarded —
Award 31· 3 suppliers
Awarded —
Award 32· 1 supplier
Awarded —
Award 33· 23 suppliers
Awarded —
Total lots
33
Awarded
33
Estimated total
£56.5m
Awarded total
—
Lot 1 Bendamustine Powder For Solution For Infusion
Start
—
End
—
Estimated
£95k
CPV
Lot 2 Capecitabine Tablets
Start
—
End
—
Estimated
£911k
CPV
Lot 3 Carboplatin Injection
Start
—
End
—
Estimated
£597k
CPV
Lot 4 Cisplatin Injection
Start
—
End
—
Estimated
£186k
CPV
Lot 5 Cyclophosphamide Injection, Powder For Reconstitution
Start
—
End
—
Estimated
£267k
CPV
Lot 6 Cytarabine Injections
Start
—
End
—
Estimated
£105k
CPV
Lot 7 Dacarbazine Injections
Start
—
End
—
Estimated
£593k
CPV
Lot 8 Disodium Folinate Injection
Start
—
End
—
Estimated
£442k
CPV
Lot 9 Docetaxel Concentrate For Solution For Infusion
Start
—
End
—
Estimated
£333k
CPV
Lot 10 Doxorubicin Hydrochloride Injections
Start
—
End
—
Estimated
£60k
CPV
Lot 12 Fluorouracil 50MG/ML Injection
Start
—
End
—
Estimated
£236k
CPV
Lot 13 Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials
Start
—
End
—
Estimated
£109k
CPV
Lot 14 Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials
Start
—
End
—
Estimated
£18k
CPV
Lot 17 Ifosfamide Injection Powder For Reconstitution
Start
—
End
—
Estimated
£2.7m
CPV
Lot 18 Irinotecan Hydrochloride Injection
Start
—
End
—
Estimated
£248k
CPV
Lot 19 Lanreotide Injection Prefilled Syringes
Start
—
End
—
Estimated
£4.7m
CPV
Lot 20 Methotrexate Without Preservatives Injection
Start
—
End
—
Estimated
£305k
CPV
Lot 21 Methotrexate Oral Solution
Start
—
End
—
Estimated
£56k
CPV
Lot 23 Oxaliplatin Vial Solution
Start
—
End
—
Estimated
£209k
CPV
Lot 24 Paclitaxel Concentrate For Intravenous Infusion
Start
—
End
—
Estimated
£407k
CPV
Lot 25 Temozolomide Capsules
Start
—
End
—
Estimated
£146k
CPV
Lot 26 Vincristine Without Preservatives Injection
Start
—
End
—
Estimated
£71k
CPV
Lot 27 Vinorelbine Injection
Start
—
End
—
Estimated
£54k
CPV
Lot 28 Aprepitant Capsules
Start
—
End
—
Estimated
£116k
CPV
Lot 31 Octreotide Injection
Start
—
End
—
Estimated
£167k
CPV
Lot 32 Filgrastim Pre-Filled Syringe
Start
—
End
—
Estimated
£1.6m
CPV
Lot 33 Pemetrexed Powder For Solution For Infusion Vials
Start
—
End
—
Estimated
£198k
CPV
Lot 34 Pemetrexed (25Mg/Ml) Solution For Infusion Vials
Start
—
End
—
Estimated
£212k
CPV
Lot 38 Dasatinib Tablets
Start
—
End
—
Estimated
£143k
CPV
Lot 39 Unranked Multi-Supplier Generic & Biosimilar Medicines
Start
—
End
—
Estimated
£10.5m
CPV
Lot 37 Etoposide Injection
Start
—
End
—
Estimated
£168k
CPV
Lot 40 Idarubicin Hydrochloride Solution for Infusion
Start
—
End
—
Estimated
£13k
CPV
Lot 41 Single Supplier Generic Medicines
Start
—
End
—
Estimated
£30.4m
CPV
Other contracts from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Accord-UK Ltd· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| NHS National Generics Pharmaceuticals - Supply Chain Resilience | contract | — | 01 May 2026 |
| NHS National Branded Interim - 1 June 2026 | contract | — | 16 Apr 2026 |
| NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide | contract | — | 26 Mar 2026 |
| Generic Drugs – Injections/Infusions 2 | contract | — | 03 Mar 2026 |
| NHS National Framework for Transition Products (Nintedanib and Dalbavancin) | contract | — | 25 Feb 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | contract | — | 14 Jan 2026 |
| NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin | contract | — | 26 Nov 2025 |
| NHS National Framework for Generics Housekeeping | contract | — | 11 Nov 2025 |